HomeAI · summaries
Storia in 3 fonti
Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international Phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple…
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- ·
medpagetoday.com
Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma
Teclistamab improved PFS, OS in patients who had received up to three previous lines of therapy
- ·
medicalxpress.com
Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard…